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Aim: Although treatment guidelines for pharmacological therapy
for schizophrenia and major depressive disorder have been
issued by the Japanese Societies of Neuropsychopharmacology
and Mood Disorders, these guidelines have not been well
applied by psychiatrists throughout the nation. To address this
issue, we developed the ‘Effectiveness of Guidelines for Dissemi-
nation and Education in Psychiatric Treatment (EGUIDE)’ inte-
grated education programs for psychiatrists to disseminate the
clinical guidelines. Additionally, we conducted a systematic efﬁ-
cacy evaluation of the programs.
Methods: Four hundred thirteen out of 461 psychiatrists
attended two 1-day educational programs based on the treat-
ment guidelines for schizophrenia and major depressive disorder
from October 2016 to March 2018. We measured the partici-
pants’ clinical knowledge of the treatment guidelines using self-
completed questionnaires administered before and after the
program to assess the effectiveness of the programs for improv-
ing knowledge. We also examined the relation between the
participants’ demographics and their clinical knowledge scores.
Results: The clinical knowledge scores for both guidelines
were signiﬁcantly improved after the program. There was no
correlation between clinical knowledge and participant
demographics for the program on schizophrenia; however, a
weak positive correlation was found between clinical knowl-
edge and the years of professional experience for the pro-
gram on major depressive disorder.
Conclusion: Our results provide evidence that educational
programs on the clinical practices recommended in guide-
lines for schizophrenia and major depressive disorder might
effectively improve participants’ clinical knowledge of the
guidelines. These data are encouraging to facilitate the stan-
dardization of clinical practices for psychiatric disorders.
Keywords: educational program, EGUIDE project, major depressive
disorder, schizophrenia, treatment guideline.
http://onlinelibrary.wiley.com/doi/10.1111/pcn.12911/full
Treatment guidelines are standard tools for clinical practice. Various
guidelines have been published for the treatment of psychiatric
disorders.1–8 In many countries, psychiatrists usually treat patients
based on treatment guidelines. However, evidence-based treatment
guidelines for psychiatric disorders were not developed in Japan until
10 years ago; as a result, Japanese psychiatrists were likely to base
clinical decisions on their own experiences. Consequently, pharmaco-
therapies for psychiatric disorders in Japan differed from those rec-
ommended by treatment guidelines in other countries.9–14 For
example, although most guidelines recommended antipsychotic mon-
otherapy for schizophrenia, the number of antipsychotics used in
Japan was higher than that used in other countries. In addition, the
use of benzodiazepines as adjunctive treatment for major depressive
disorder, which is not recommended in most guidelines, was higher
in Japan than in the USA.6 To address these situations, the ‘Guideline
for Pharmacological Therapy for Schizophrenia’ was published by the
Japanese Society of Neuropsychopharmacology in 2015,15 and the
‘Treatment Guideline: Major Depressive Disorder’ was published by
the Japanese Society of Mood Disorders in 201216 and revised as the
‘Treatment Guideline II: Major Depressive Disorder’ in 2016.17
Although treatment guidelines for schizophrenia and major
depressive disorder have been published, pharmacological treatment
for these disorders in Japan has still not changed.9,10 One possible
reason for this phenomenon is that there has been no ofﬁcial training
program for learning the treatment guidelines by academic societies
for psychiatrists and residents in Japan. Consequently, we realized the
need to disseminate the guidelines to Japanese psychiatrists and pro-
vide education regarding the guidelines’ content. Therefore, we
started the ‘Effectiveness of Guidelines for Dissemination and Educa-
tion in Psychiatric Treatment’ (EGUIDE) project in 2016 to dissemi-
nate the guidelines. The aims of the EGUIDE project were to
disseminate the guidelines via education programs for psychiatrists
that present the treatment guidelines for schizophrenia and major
depressive disorder. In addition, we investigated the effectiveness of
the guideline education programs by evaluating the participants’ clini-
cal knowledge regarding the guidelines before and after the programs.
The aim of this study was to access the dissemination of the
guidelines via educational programs for psychiatrists throughout
Japan. Moreover, we evaluated the educational effect of the programs
for each psychiatrist by comparing his or her knowledge of the treat-
ment guidelines before and after the programs.
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Methods
Design and participants
Psychiatrists were recruited from October 2016 to March 2018. Writ-
ten informed consent was obtained for all participants after the proce-
dures had been fully explained by a chief researcher at the facility.
This study was approved by the ethics committees of the National
Center of Neurology and Psychiatry (A2017-105) and each participat-
ing university/hospital/clinic. The study procedures were conducted
according to the Declaration of Helsinki. The protocol of this study
was registered in the University Hospital Medical Information Net-
work registry (UMIN000022645). Initially, the participants completed
a self-administered questionnaire that assessed their knowledge of
clinical guidelines. The participants then attended 1-day educational
programs on schizophrenia and depression based on the ‘Guideline
for Pharmacological Therapy for Schizophrenia’ published by the Jap-
anese Society of Neuropsychopharmacology and the ‘Treatment
Guideline II: Major Depressive Disorder’ published by the Japanese
Society of Mood Disorders. Lectures on the guidelines and discus-
sions of two clinical cases were included to present the guidelines and
to describe how to implement them in practice. The participants then
retook the self-administered questionnaire at the end of the 1-day pro-
gram. The efﬁcacy of each program was evaluated according to the
changes in the scores of the self-administered questionnaires between
baseline and program completion.
Assessment measures
To evaluate the participants’ clinical knowledge of the ‘Guideline
for Pharmacological Therapy for Schizophrenia,’ we created a self-
administered questionnaire consisting of 37 items (a total of
37 points) with seven subscale scores (Table S1). The participants’
clinical knowledge of the ‘Treatment Guideline II: Major Depressive
Disorder’ was evaluated via another self-administered questionnaire
consisting of 37 items (a total of 37 points) with eight subscale
scores (Table S1 and S2). All items were described in Japanese and
required checking correct or incorrect in the square for each ques-
tion. The participants were asked to answer all questions within
7 min. We excluded all subjects with any incomplete data for the
two guideline tests (at baseline and after the program), such as miss-
ing checks in the squares for each question, which we regarded as
missing data.
Statistical analysis
All statistical analyses were performed using Excel (Microsoft, Red-
mond, WA, USA) or SPSS 22.0 (SPSS, Chicago, IL, USA). The
Kolmogorov–Smirnov test was used to evaluate the normality of the
clinical knowledge scores and participants’ ages and professional
experience. The data were analyzed with tests for matched pairs using
statistical signiﬁcance and effect size estimates. To compare the
changes in the total clinical knowledge scores between baseline and
post-program for matched pairs, the Wilcoxon signed-rank test was
used. Effect sizes were determined with Z-values divided by the
square root of the number of subjects. The rates of correct answers at
baseline and post-program for each item were compared using χ2
tests. The relations among sex, age, professional experience, and clin-
ical knowledge scores at baseline and post-program were analyzed
using Spearman’s rank correlation coefﬁcient. To identify associated
factors for the total clinical knowledge scores in each program, multi-
ple regression analysis was performed with three independent vari-
ables (age, sex, and professional experience).
The signiﬁcance level was set at P < 0.05. The Bonferroni cor-
rection was applied for multiple testing.
Results
Participant demographics
A total of 443 participants attended the ‘Guideline for Pharmacologi-
cal Therapy for Schizophrenia’ program, and 431 attended the ‘Treat-
ment Guideline II: Major Depressive Disorder’ program over the
18-month period. The participants represented over 90 medical insti-
tutions. Of 413 participants who participated in both programs, we
used the data of 344 psychiatrists in the ﬁnal analysis (Fig. S1). The
demographics of the 344 psychiatrists are summarized in Table S3. A
normal distribution was not observed for the participants’ ages and
years of professional experience (Fig. S2).
Changes in the clinical knowledge scores before and
after the program
The distribution of clinical knowledge scores before and after
attending the educational program on the ‘Guideline for Pharma-
cological Therapy for Schizophrenia’ is shown in Figure 1a. The
results showed that the vertex of the distribution of clinical knowl-
edge scores shifted signiﬁcantly to the right after the program
(χ2 = 348.17, P = 1.9 × 10−66). Table 1 shows the means and
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statistical results for the total clinical knowledge score and sub-
scale scores before and after the program. The accuracy rate of
total clinical knowledge score increased signiﬁcantly, from 90.3%
(baseline) to 98.1% (after the program), as shown in Table 1
(Z = 15.02, P = 5.3 × 10−51, r = 0.81). Regarding the subscales of
clinical knowledge, large and signiﬁcant changes were observed
in ‘Recommended pharmacotherapy for schizophrenia in general’
(Z = 9.45, P = 3.4 × 10−21, r = 0.51), ‘Management of recurrence
or relapse of schizophrenia’ (Z = 12.48, P = 9.4 × 10−36,
r = 0.67), ‘Pharmacotherapy during the maintenance phase’
(Z = 13.34, P = 1.3 × 10−40, r = 0.72.), and ‘Management of
treatment-resistant schizophrenia’ (Z = 9.73, P = 2.4 × 10−22,
r = 0.52). In addition, signiﬁcant and moderate changes were observed
in ‘Other issues’ (Z = 6.21, P = 5.3 × 10−10, r = 0.34). A comparison
of the correct answer rate for each item between baseline and post-
program is shown in Table S4. The accuracy rates were increased for
most questions; the exceptions were F-3 and G-8.
Table 1. Comparison of clinical knowledge scores at baseline and after the ‘Guideline for Pharmacological Therapy for Schizophrenia’ program
Baseline Post-program Statistic
Mean SD %† Mean SD %† Z‡ P r
Total clinical knowledge score 33.4 2.3 90.3 36.3 0.9 98.1 15.02 5.3 × 10−51 0.81
Clinical knowledge subscale scores
Recommended pharmacotherapy for schizophrenia in
general
3.6 0.6 90.5 4.0 0.1 99.9 9.45 3.4 × 10−21 0.51
Recommended pharmacotherapy for ﬁrst-episode
psychosis
4.9 0.3 98.5 5.0 0.1 99.8 3.82 1.3 × 10−4 0.21
Duration of pharmacotherapy for ﬁrst-episode
psychosis in terms of relapse prevention
2.8 0.6 93.9 3.0 0.1 99.9 5.49 4.1 × 10−8 0.30
Management of recurrence or relapse of schizophrenia 4.1 0.6 82.5 4.8 0.5 95.0 12.48 9.4 × 10−36 0.67
Pharmacotherapy during the maintenance phase 4.9 0.9 82.0 5.8 0.4 97.5 13.34 1.3 × 10−40 0.72
Management of treatment-resistant schizophrenia 5.3 0.8 88.2 5.8 0.4 96.7 9.73 2.4 × 10−22 0.52
Other issues 7.7 0.5 96.5 7.9 0.3 98.9 6.21 5.3 × 10−10 0.34
†Percentage of correct answers.
‡The Wilcoxon signed-ranks test was used for the statistical analysis as the Kolmogorov–Smirnov test did not indicate a normal distribution of
clinical knowledge scores at baseline or after the program (P = 3.1 × 10−25, P = 1.0 × 10−83).
An effect size (r) of 0.5 or more indicates a large change, and an effect size (r) of 0.3 to 0.5 indicates a moderate change.
The signiﬁcance level was set at two-tailed P < 6.3 × 10−3 as the Bonferroni method was applied.
Signiﬁcant P-values are boldfaced.
Table 2. Comparison of clinical knowledge scores at baseline and after the ‘Treatment Guideline II: Major Depressive Disorder’ program
Baseline Post-program Statistic
Mean SD %† Mean SD %† Z‡ P r
Total clinical knowledge score 31.2 2.7 84.4 34.6 1.7 93.5 15.27 1.3 × 10−52 0.82
Clinical knowledge subscale scores
Diagnosis of major depressive disorder (DSM-5) 4.6 1.0 76.1 5.4 0.6 90.3 12.39 3.1 × 10−35 0.67
Treatment of major depressive disorder 4.2 0.6 84.1 4.4 0.6 87.6 4.86 1.2 × 10−6 0.26
Management of mild depression 5.8 0.9 82.1 6.4 0.7 92.1 10.69 1.1 × 10−26 0.58
Recommended treatment for moderate/severe depression 3.4 0.7 85.3 3.7 0.5 93.4 7.49 6.7 × 10−14 0.40
Recommended treatment for moderate/severe depression,
if necessary
2.8 0.5 93.8 3.0 0.1 99.5 5.86 4.6 × 10−9 0.32
Management of psychotic depression 2.9 1.1 72.5 3.7 0.7 92.9 11.27 1.9 × 10−29 0.61
Management of depression in children and adolescents 3.8 0.5 94.0 4.0 0.2 99.3 7.41 1.2 × 10−13 0.40
Management of sleep disorders associated with
depression
3.8 0.4 95.8 4.0 0.2 98.8 4.98 6.5 × 10−7 0.27
†Percentage of correct answers.
‡The Wilcoxon signed-ranks test was used for the statistical analysis as the Kolmogorov–Smirnov test did not indicate normal distribution of
clinical knowledge scores at baseline or after the program (P = 1.0 × 10−17, P = 6.6 × 10−37).
An effect size (r) of 0.5 or more indicates a large change, and an effect size (r) of 0.3 to 0.5 indicates moderate change.
The signiﬁcance level was set at two-tailed P< 6.3 × 10−3 as the Bonferroni method was applied.
Signiﬁcant P-values are boldfaced.
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The distribution of clinical knowledge scores before and after
the ‘Treatment Guideline II: Major Depressive Disorder’ educational
program is shown in Figure 1b. Similarly, the vertex of the distribu-
tion of clinical knowledge scores shifted to the right (χ2 = 279.37,
P = 2.3 × 10−51). Table 2 shows the mean scores and the statisti-
cal results before and after the program for the total clinical
knowledge and subscales. The correct answer rate for the total
clinical knowledge score increased signiﬁcantly, from 84.4%
(baseline) to 93.5% (after the program; Z = 15.27,
P = 1.3 × 10−52, r = 0.82). Regarding the subscales of clinical
knowledge, signiﬁcant and large changes were observed in ‘Diag-
nosis of major depressive disorder (DSM-5)’ (Z = 12.39,
P = 3.1 × 10−35, r = 0.67), ‘Management of mild depression’
(Z = 10.69, P = 1.1 × 10−26, r = 0.58), and ‘Management of psy-
chotic depression’ (Z = 11.27, P = 1.9 × 10−29, r = 0.61). In addi-
tion, signiﬁcant and moderate changes were observed in
‘Recommended treatment for moderate/severe depression’
(Z = 7.49, P = 6.7 × 10−14, r = 0.40), ‘Recommended treatment
for moderate/severe depression if necessary’ (Z = 5.86,
P = 4.6 × 10−9, r = 0.32), and ‘Management of depression in chil-
dren and adolescents’ (Z = 7.41, P = 1.2 × 10−13, r = 0.40). A
comparison of the correct answer rates for each item between the
baseline and after the program is shown in Table S5. The accuracy
rates were increased for most questions; the exceptions were B-3
and C-2.
Relations between the clinical knowledge score and
participant demographics
Table 3 shows the relations between the total clinical knowledge
score (before and after the program) and the participant demographics
for each guideline. In the ‘Guideline for Pharmacological Therapy for
Schizophrenia’ program, there was no correlation between the total
clinical knowledge score and the participant demographics. The distri-
bution of clinical knowledge scores by years of professional experi-
ence is shown in Fig. S3a.
For the ‘Treatment Guideline II: Major Depressive Disorder’
program, a weak positive correlation was found between the total clin-
ical knowledge score at the baseline and the years of professional
experience (ρ = 0.28, P = 1.8 × 10−7; Table 3). Additionally, a very
weak positive correlation was found between the total clinical knowl-
edge score after the program and the years of professional experience
(ρ = 0.18, P = 7.7 × 10−4). There was no correlation between the total
clinical knowledge score and the sex or age of the participants. The
Table 3. Relation between the clinical knowledge score and participant demographics
Sex Age Professional experience
ρ† P ρ† P ρ† P
Medical education program for the ‘Treatment Guideline for Pharmacological Therapy for Schizophrenia’
Total clinical knowledge score at baseline −0.09 0.11 0.02 0.74 0.07 0.17
Total clinical knowledge score after the program −0.04 0.48 −0.06 0.29 0.01 0.83
Medical education program for ‘Treatment Guideline II: Major Depressive Disorder’
Total clinical knowledge score at baseline −0.09 0.11 0.10 0.05 0.28 1.8 × 10−7
Total clinical knowledge score after the program −0.05 0.38 0.05 0.39 0.18 7.7 × 10−4
†Spearman’s rank correlation coefﬁcient.
The signiﬁcance level was set at two-tailed P < 6.3 × 10−3 as the Bonferroni method was applied.
A correlation coefﬁcient (ρ) of 0.2 to 0.4 indicates a weak correlation.
Signiﬁcant P-values are boldfaced.
Table 4. Results of multiple regression analyses of the clinical knowledge scores
Sex Age
Professional
experience
Beta† P Beta† P Beta† P
Adjusted
R2
ANOVA
P
Medical education program for the ‘Treatment Guideline for Pharmacological Therapy for Schizophrenia’
Total clinical knowledge score at baseline −0.05 0.33 −0.12 0.14 0.18 2.5 × 10−2 0.019 8.7 × 10−2
Total clinical knowledge score after the
program
−0.05 0.38 −0.18 2.9 × 10−2 0.15 0.06 0.008 0.13
Medical education program for ‘Treatment Guideline II: Major Depressive Disorder’
Total clinical knowledge score at baseline −0.06 0.26 −0.22 5.0 × 10−3 0.41 2.6 × 10−7 0.081 6.0 × 10−7
Total clinical knowledge score after the
program
−0.02 0.79 −0.21 8.0 × 10−3 0.35 1.6 × 10−5 0.048 1.8 × 10−4
†Standardized partial regression coefﬁcient.
The signiﬁcance level was set at two-tailed P < 1.25 × 10−2 as the Bonferroni method was applied.
Signiﬁcant P-values are boldfaced.
ANOVA, analysis of variance.
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distribution of the clinical knowledge scores by years of professional
experience is shown in Fig. S3b.
The results of multiple regression analysis revealed that there was
no signiﬁcant factor associated with total clinical knowledge in the
‘Guideline for Pharmacological Therapy for Schizophrenia’ program
(Table 4). On the other hand, age and professional experience were sig-
niﬁcantly associated with total clinical knowledge scores both at base-
line (beta = −0.22, P = 5.0 × 10−3 and beta = 0.41, P = 2.6 × 10−7,
respectively) and after the program (beta = −0.21, P = 8.0 × 10−3 and
beta = 0.35, P = 1.6 × 10−5, respectively) in the ‘Treatment Guideline
II: Major Depressive Disorder’ program (Table 4).
Discussion
This is the ﬁrst study to investigate the dissemination of treatment
guidelines for schizophrenia and major depressive disorder and to
evaluate the effectiveness of an educational program on the guidelines
at the same time. Approximately half (n = 42) of the 82 university
hospitals mainly responsible for psychiatric professional education in
Japan participated in the EGUIDE project, and 344 psychiatrists
attended educational programs aimed at ensuring an appropriate
understanding of the guidelines (Fig. S4). Previous studies have
suggested that there could be a huge gap between the development of
guidelines based on research evidence and their uptake in clinical
practice.18 Although the pathway from evidence to guideline is highly
developed, the pathway from guideline to clinical practices is much
less developed and has been examined in few studies.19–21 This situa-
tion suggests that a lack of awareness of and familiarity with guide-
lines, as well as lack of a supply system, might prevent the
implementation of guidelines in clinical practice. To address these
issues, the EGUIDE project created a supply system and provided an
opportunity for clinicians to become aware of and familiar with the
guidelines. Consequently, the EGUIDE project was used to dissemi-
nate and encourage the implementation of guidelines in clinical prac-
tice throughout Japan.
Regarding the effects of the educational program on the partici-
pants’ understanding of the guidelines, the results of this study
showed that knowledge of the guidelines was signiﬁcantly improved
after the programs for schizophrenia and major depressive disorder.
These results suggest that our educational programs can be useful for
improving knowledge of treatment guidelines.
In this study, we performed multiple regression analysis for fac-
tors possibly associated with clinical knowledge score of each guide-
line before and after the program in independent variables (sex, age,
and professional experience). As a result, clinical knowledge scores
in the ‘Treatment Guideline II: Major Depressive Disorder’ program
were negatively associated with age and positively associated with
professional experience. However, it is difﬁcult to explain these
results with our limited data. There might be various potential con-
founding factors associated with the clinical knowledge scores of
guidelines. Therefore, it is difﬁcult to draw any conclusions regarding
the relations observed in this study.
The ‘Guideline for Pharmacological Therapy for Schizophrenia’
emphasizes that antipsychotic monotherapy should be considered as a
ﬁrst-line treatment for all patients with schizophrenia and that cloza-
pine should be used for treatment-resistant schizophrenia, similar to
the guidelines of other countries.1,4,6–8 However, Japanese psychia-
trists are more likely than psychiatrists in other countries to
adjunctively prescribe multiple antipsychotics and other psychotro-
pics, such as benzodiazepines, instead of antipsychotics mon-
otherapy.11,13,14 In addition, fewer treatment-resistant schizophrenia
patients in Japan take clozapine.22 Taking these situations and the
results of this study into consideration, signiﬁcant improvement in
total clinical knowledge scores, including recommendations regarding
the appropriate use of antipsychotic monotherapy and clozapine, may
lead to the implementation of appropriate pharmacological therapy
for schizophrenia in Japan.
For ‘Treatment Guideline II: Major Depressive Disorder,’ the
degree of knowledge about the guideline was signiﬁcantly improved
after the program. ‘Treatment Guideline II: Major Depressive Disorder’
recommends antidepressants as the ﬁrst-line treatment for major depres-
sive disorder and does not recommended long-term use of benzodiaze-
pines. However, a majority of major depressive disorder patients in
Japan are not treated according to guidelines, and many patients are
treated with multiple drugs, including long-term use of benzodiaze-
pines.23 In addition, according to the study comparing the treatment
choices for major depressive disorder between Japanese and US
psychiatrists,12 the Japanese psychiatrists favored benzodiazepine mon-
otherapy for the treatment of mild major depressive disorder, whereas
the US psychiatrists favored antidepressant monotherapy. Given these
situations, this study’s ﬁndings of a signiﬁcant increase in the total score
for clinical knowledge of the guidelines, including the appropriate use
of antidepressants and benzodiazepines, may have a positive inﬂuence
on the clinical treatment of major depressive disorder in Japan.
Several limitations of this study should be considered when inter-
preting the results. First, it was difﬁcult to evaluate the effect of the
program because of the nature of the study, which was conducted as a
single-arm design without a control group. Second, because the ques-
tionnaires used were not validated, it was unclear whether the question-
naire could appropriately evaluate the knowledge of the guidelines.
Third, it can be presumed that the participants’ background information
was insufﬁcient, and there may be multiple potential confounding fac-
tors related to improving understanding of the guidelines. Fourth, it is
necessary not only to evaluate the knowledge of clinical guidelines but
also to evaluate changes in quality indicators, such as the participants’
prescription patterns, to verify the effects of the program. Fifth, the dis-
tribution of the age of participants was relatively young. This could be
due to the design of this clinical implementation research. Research
and education programs are common in the university hospitals that
participated in the EGUIDE project and young psychiatrists tend to
outnumber older psychiatrists in university hospitals. It might be difﬁ-
cult to generalize the results to all psychiatrists in Japan due to the
selection bias. Although this study was a preliminary survey, dissemi-
nating clinical guidelines and educating psychiatrists about clinical
guidelines will lead to meaningful results in clinical settings. The
EGUIDE project could provide not only for psychiatrists working for
university hospitals but for all Japanese psychiatrists and residents in
the future. To achieve this, the EGUIDE projects would need to collab-
orate with the ofﬁcial programs of academic societies in Japan. More-
over, comprehensive treatment guidelines, including psychosocial
interventions and pharmacological treatment for achieving recovery,
should be developed.24
In conclusion, the EGUIDE project, a dissemination and educa-
tion program for the ‘Guideline for Pharmacological Therapy for
Schizophrenia’ and ‘Treatment Guideline II: Major Depressive
Disorder,’ could help to improve clinical knowledge regarding the
guidelines among psychiatrists. Further study will be needed to clar-
ify the effects of the EGUIDE project on the improvement of inappro-
priate pharmacological treatment in clinical settings.
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Additional Supporting Information may be found in the online ver-
sion of this article at the publisher’s web-site:
Fig. S1 Flow chart of the study participants. During the 18-month
study period, there were 445 participants in the ‘Guideline for Phar-
macological Therapy for Schizophrenia’ and 433 participants in the
‘Treatment Guideline II: Major Depressive Disorder’ program. The
participants represented over 90 medical institutions. Of these partici-
pants, we used the data of 344 in the ﬁnal analysis.
Fig. S2 Distribution of age and years of professional experience. Dis-
tribution of demographics. (a) Age. (b) Years of professional experi-
ence. The Kolmogorov–Smirnov test was conducted. Normal
distribution was not observed for (a) and (b) (A: P = 6.3 × 10−20, B:
P = 5.5 × 10−59).
Fig. S3 The distribution of clinical knowledge scores for years of pro-
fessional experience in the guidelines for schizophrenia and major
depressive disorder. The distribution of clinical knowledge scores for
each year of professional experience. (a) ‘Guideline for Pharmacolog-
ical Therapy for Schizophrenia.’ (b) ‘Treatment Guideline II: Major
Depressive Disorder.’ Error bars indicate standard deviation.
Fig. S4 Distribution of the facilities that participated in this study in
Japan. Of a total of 82 university hospitals in Japan, approximately
half (n = 42) joined the EGUIDE project (10 March 2019).
Table S1. Questions regarding knowledge about the pharmacotherapy
of schizophrenia
Table S2. Questions regarding knowledge about the management of
major depressive disorder
Table S3. Participant demographics
Table S4. Detailed comparison of clinical knowledge scores at base-
line and after the ‘Guideline for Pharmacological Therapy for Schizo-
phrenia’ program
Table S5. Detailed comparison of clinical knowledge scores at base-
line and after the ‘Treatment Guideline II: Major Depressive Disor-
der’ program
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